Kodu・Aktsiate loetelu・Geron Corp

Geron Corp

Suletud

SektorTervishoid

1.43 -0.69

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.42

Max

1.43

Põhinäitajad
By Trading Economics
Sissetulek	25M -3.6M
Müük	3.8M 52M
Aktsiakasum	-0.005
Kasumimarginaal	-7.026
Töötajad	258
EBITDA	27M 3.8M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+181.69% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-82M 924M
Eelmine avamishind	2.12
Eelmine sulgemishind	1.43

Uudiste sentiment

By Acuity

50%

152 / 340 Pingereas Healthcare

Geron Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. juuli 2026, 19:46 UTC

Geron Corp shares are lower in Friday's session amid broader market volatility and uncertainty from fluctuating oil prices and new U.S. tariffs.

23. juuli 2026, 10:11 UTC

Shares of Geron Corp are higher in pre-market hours, trading above their 20-day moving average. No specific company news was identified.

22. juuli 2026, 18:51 UTC

Geron Corp shares are lower today amid broader market trends, as crude oil prices surge due to geopolitical tensions.

21. juuli 2026, 23:41 UTC

Geron Corp shares are lower in after-market trading, declining to their lowest point since Tuesday's close. No specific news was identified to explain the drop.

20. juuli 2026, 23:56 UTC

Geron Corp shares are lower in after-market hours, continuing a decline since Monday's close amid broader market uncertainties and a drop in the leading economic index.

Võrdlus sarnastega

Hinnamuutus

Geron Corp Prognoos

Hinnasiht

By TipRanks

181.69% tõus

12 kuu keskmine prognoos

Keskmine 4 USD 181.69%

Kõrge 5 USD

Madal 3 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Geron Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Geron Corp aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

152 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.